These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 39036117)

  • 1. Unlocking the Therapeutic Symphony: A Systematic Review Exploring the Role of Levosimendan in the Management of Heart Failure.
    Ali R; Sajjad W; Mushtaq I; Farooqi H; Sohail A; Wazir Khan H; Tabasum P; Haseeb A; Ismail WU
    Cureus; 2024 Jun; 16(6):e62799. PubMed ID: 39036117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Safety and efficacy of the early administration of levosimendan in patients with acute non-ST-segment elevation myocardial infarction and elevated NT-proBNP levels: An Early Management Strategy of Acute Heart Failure (EMS-AHF)].
    Xu F; Bian Y; Zhang GQ; Gao LY; Liu YF; Liu TX; Li G; Song RX; Su LJ; Zhou YJ; Cui JY; Yan XL; Guo FM; Zhang HY; Li QH; Zhao M; Ma LK; You BA; Wang G; Kong L; Ma JL; Zhou XF; Chang ZL; Tang ZY; Yu DY; Cheng K; Xue L; Li X; Pang JJ; Wang JL; Zhang HT; Yu XZ; Chen YG
    Zhonghua Nei Ke Za Zhi; 2023 Apr; 62(4):374-383. PubMed ID: 37032132
    [No Abstract]   [Full Text] [Related]  

  • 3. Levosimendan Can Improve the Level of B-Type Natriuretic Peptide and the Left Ventricular Ejection Fraction of Patients with Advanced Heart Failure: A Meta-analysis of Randomized Controlled Trials.
    Cui D; Liao Y; Li G; Chen Y
    Am J Cardiovasc Drugs; 2021 Jan; 21(1):73-81. PubMed ID: 32462455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-Analysis of the Efficacy of Levosimendan in the Treatment of Severe Sepsis Complicated with Septic Cardiomyopathy.
    Guan Q; Zhang C; Li B; Huang D; Li A; Qin J; Zhang X
    Heart Surg Forum; 2023 Oct; 26(5):E609-E620. PubMed ID: 37920078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of levosimendan in patients with cardiac amyloidosis.
    Aimo A; Arzilli C; Castiglione V; Morfino P; Panichella G; Passino C; Vergaro G; Emdin M
    Int J Cardiol; 2024 Jun; 405():131963. PubMed ID: 38479497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved heart function and cardiac remodelling following sacubitril/valsartan in acute coronary syndrome with HF.
    Liu H; Su Y; Shen J; Jiao Y; Li Y; Liu B; Hou X; Jin Q; Chen Y; Sun Z; Xi Q; Feng B; Fu Z
    ESC Heart Fail; 2024 Apr; 11(2):937-949. PubMed ID: 38224955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levosimendan in outpatients with advanced heart failure: Single-center experience of 200 intermittent perfusions.
    Ferreira Reis J; Valentim Gonçalves A; Ilhão Moreira R; Pereira da Silva T; Timóteo AT; Pombo D; Carvalho T; Correia C; Santos C; Cruz Ferreira R
    Rev Port Cardiol; 2023 Apr; 42(4):335-343. PubMed ID: 36634758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term efficacy and safety of levosimendan in patients with chronic systolic heart failure.
    Cui XR; Yang XH; Li RB; Wang D; Jia M; Bai L; Zhang JD
    Cardiovasc J Afr; 2020; 31(4):196-200. PubMed ID: 32555927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
    Felker GM; Anstrom KJ; Adams KF; Ezekowitz JA; Fiuzat M; Houston-Miller N; Januzzi JL; Mark DB; Piña IL; Passmore G; Whellan DJ; Yang H; Cooper LS; Leifer ES; Desvigne-Nickens P; O'Connor CM
    JAMA; 2017 Aug; 318(8):713-720. PubMed ID: 28829876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure.
    Oner E; Erturk M; Birant A; Kurtar Mansıroglu A; Akturk IF; Karakurt H; Yalcin AA; Uzun F; Somuncu MU; Yildirim A
    Cardiol J; 2015; 22(1):87-93. PubMed ID: 24846511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of levosimendan on the right ventricular function in patients with right ventricular dysfunction undergoing mitral valve surgery.
    Bharathi KS; Pruthi G; Dhananjaya M; Simha PP
    Ann Card Anaesth; 2023; 26(1):50-56. PubMed ID: 36722588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of levosimendan on heart failure in normotensive patients: does loading dose matter?
    Palmerini E; Söderberg S; Mondillo S; Favilli R; Lunghetti S
    Acute Card Care; 2015 Mar; 17(1):14-9. PubMed ID: 25806830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levosimendan Improves Clinical Outcomes of Refractory Heart Failure in Elderly Chinese Patients.
    Zhang D; Yao Y; Qian J; Huang J
    Med Sci Monit; 2015 Aug; 21():2439-45. PubMed ID: 26289557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.
    Butt JH; Adamson C; Docherty KF; de Boer RA; Petrie MC; Inzucchi SE; Kosiborod MN; Maria Langkilde A; Lindholm D; Martinez FA; Bengtsson O; Schou M; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV; Køber L
    Circ Heart Fail; 2021 Dec; 14(12):e008837. PubMed ID: 34802253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermittent inotropic therapy with levosimendan vs. milrinone in advanced heart failure patients.
    Milwidsky A; Frydman S; Laufer-Perl M; Sadeh B; Sapir O; Granot Y; Hochstadt A; Korotetski L; Ketchker L; Topilsky Y; Banai S; Havakuk O
    ESC Heart Fail; 2022 Apr; 9(2):1487-1491. PubMed ID: 35083882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period: The multinational randomized LeoDOR trial.
    Pölzl G; Altenberger J; Comín-Colet J; Delgado JF; Fedele F; García-González MJ; Gustafsson F; Masip J; Papp Z; Störk S; Ulmer H; Maier S; Vrtovec B; Wikström G; Zima E; Bauer A;
    Eur J Heart Fail; 2023 Nov; 25(11):2007-2017. PubMed ID: 37634941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
    Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
    Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced External Counterpulsation (EECP): An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(5):1-70. PubMed ID: 23074496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial.
    Comín-Colet J; Manito N; Segovia-Cubero J; Delgado J; García Pinilla JM; Almenar L; Crespo-Leiro MG; Sionis A; Blasco T; Pascual-Figal D; Gonzalez-Vilchez F; Lambert-Rodríguez JL; Grau M; Bruguera J;
    Eur J Heart Fail; 2018 Jul; 20(7):1128-1136. PubMed ID: 29405611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.